12-year biologic exclusivity could keep costs high, AARP says

10/24/2013 | Hill, The

AARP wrote a letter this week to U.S. Trade Representative Michael Froman to urge that the Trans-Pacific Partnership not include proposals that would tie the U.S. to a market exclusivity period of 12 years for brand-name biologic drugs. "With annual costs that can reach as high as $400,000, the high price of biologic drugs not only has adverse effects on consumers, but also on other health care payers, including public programs like Medicare and Medicaid," the group wrote. Supporters said drugmakers won't yield returns on their investments in drug research and development without the 12-year window.

View Full Article in:

Hill, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR